What is the 13F Pro Quality Score for FHTX?

13F Pro ranks Foghorn Therapeutics Inc. (FHTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View FHTX's current score at https://13fpro.ai/research/FHTX (free sign-up required for the full ranking).

Which hedge funds own the most FHTX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of FHTX include Flagship Pioneering, FMR, BVF /IL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/FHTX as soon as new 13F filings post.

Where does 13F Pro source FHTX data?

All Foghorn Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. Foghorn Therapeutics Inc. files with the SEC under CIK 1822462. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is FHTX in?

Foghorn Therapeutics Inc. (FHTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is FHTX research updated on 13F Pro?

FHTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Foghorn Therapeutics Inc.(FHTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1822462 FHTX stock profile & AI dashboard →

13F Pro Quality Score

11.2/100

Rank #2,797 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

9.6/100

Profitability

4.4/100

Balance Sheet

5.5/100

Earnings Quality

30.0/100

Free Cash Flow

3.9/100

Institutional Flow

85.7/100

Revenue Scale

6.1/100

Dilution Risk

5.9/100

FHTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Foghorn Therapeutics Inc. (FHTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FHTX at 11.2/100 on a 32-signal composite quality model, placing it at rank #2,797 of 2,879 stocks — the bottom half of the AI-ranked universe. FHTX scores in the top quartile across institutional flow (85.7). Areas of concern include free cash flow (3.9) and profitability (4.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Foghorn Therapeutics Inc. reports quarterly revenue of $3.3M, net income of $-19.9M, free cash flow of $-25.3M. Top institutional holders of FHTX by reported 13-F value include Flagship Pioneering, FMR, BVF /IL, based on the most recent SEC filings. FHTX trades on the Nasdaq exchange and files with the SEC under CIK 1822462. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FHTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Foghorn Therapeutics Inc. directly from SEC EDGAR. Foghorn Therapeutics Inc.'s 13F Pro composite quality score has ranged between 9 and 42 since 2021, currently 11.2 — a declining long-term trajectory across 27 quarterly and live scoring snapshots.

✦

Fun facts about Foghorn Therapeutics Inc.

Quirks, history, and lore behind FHTX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Cambridge, Massachusetts.
2
The Numbers
Like most clinical-stage biotechs, it carries no product revenue and burns cash on R&D — operating losses have run into the tens of millions of dollars per year while it funds its pipeline.
3
The History
Founded around 2016, it went public in 2020 and built its entire scientific identity around a single, then-underexplored region of the genome that most drug hunters had ignored.
4
The Secret
Its core bet is on the chromatin regulatory system — the molecular machinery that controls which genes get switched on or off — as a target for cancer therapies.
5
The Lore
It has pursued drugs that block the COMPASS-like complex, a protein assembly linked to certain hard-to-treat tumors — niche science that gives it a very distinctive research fingerprint in oncology.
6
The Giveaway
Its name evokes a barnyard loudmouth, its ticker is FHTX, and its mission is to silence the wrong genes in cancer — one chromatin complex at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$3.3M

Net Income

Q1 2026

$-19.9M

Free Cash Flow

Q1 2026

$-25.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+36.8% YoY

$30.9MFY 2025

FY21 $1.3MFY22 $19.2MFY24 $22.6MFY25 $30.9M

Net Income

+14.2% YoY

$-74.3MFY 2025

FY21 $-101.3MFY22 $-108.9MFY24 $-86.6MFY25 $-74.3M

Operating Income

+15.9% YoY

$-86.4MFY 2025

FY21 $-100.7MFY22 $-117.1MFY24 $-102.7MFY25 $-86.4M

EPS (Diluted)

+25.3% YoY

$-1.18FY 2025

FY21 $-2.73FY22 $-2.62FY24 $-1.58FY25 $-1.18

Total Assets

-30.2% YoY

$198.1MFY 2025

FY21 $519.8MFY22 $404.9MFY24 $284.0MFY25 $198.1M

Total Debt

—FY 2025

FY21 $0.00FY22 —FY24 —FY25 —

Op. Cash Flow

+14.2% YoY

$-86.1MFY 2025

FY21 $-50.3MFY22 $193.6MFY24 $-100.4MFY25 $-86.1M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2019	FY 2018
Revenue	$30.9M +36.8%	$22.6M +17.5%	$19.2M +1357.8%	$1.3M	—	—
Net Income	$-74.3M +14.2%	$-86.6M +20.4%	$-108.9M -7.5%	$-101.3M -98.2%	$-51.1M	—
Operating Income	$-86.4M +15.9%	$-102.7M +12.3%	$-117.1M -16.3%	$-100.7M -97.2%	$-51.1M	—
EPS (Diluted)	$-1.18 +25.3%	$-1.58 +39.7%	$-2.62 +4.0%	$-2.73	—	—
Total Assets	$198.1M -30.2%	$284.0M -29.9%	$404.9M -22.1%	$519.8M +2226.4%	$22.3M	—
Total Debt	—	—	—	$0.00 -100.0%	$15.1M	—
Operating Cash Flow	$-86.1M +14.2%	$-100.4M -151.9%	$193.6M +485.3%	$-50.3M -8.4%	$-46.3M	—

Get alerted when FHTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Foghorn Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of FHTX

Flagship Pioneering Inc.
$60.6M12,674,120 sh
FMR LLC
$28.9M6,047,198 sh
BVF INC/IL
$27.9M5,842,000 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$21.0M4,394,367 sh
RAYMOND JAMES FINANCIAL INC
$12.4M2,602,382 sh
BlackRock, Inc.
$11.3M2,364,866 sh
Euclidean Capital LLC
$7.5M1,573,761 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.1M1,495,089 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.1M848,172 sh
Siren, L.L.C.
$3.4M720,720 sh

Fund	Value	Shares
Flagship Pioneering Inc.	$60.6M	12,674,120
FMR LLC	$28.9M	6,047,198
BVF INC/IL	$27.9M	5,842,000
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$21.0M	4,394,367
RAYMOND JAMES FINANCIAL INC	$12.4M	2,602,382
BlackRock, Inc.	$11.3M	2,364,866
Euclidean Capital LLC	$7.5M	1,573,761
VANGUARD CAPITAL MANAGEMENT LLC	$7.1M	1,495,089
GEODE CAPITAL MANAGEMENT, LLC	$4.1M	848,172
Siren, L.L.C.	$3.4M	720,720

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put FHTX on your watchlist

Track score changes the day Foghorn Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is FHTX a good stock to buy?

13F Pro's AI-powered analysis of Foghorn Therapeutics Inc. (FHTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FHTX are available on the FHTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own FHTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FHTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Foghorn Therapeutics Inc.'s investment landscape.